



Conflicts of interest


 Have given lectures at meetings sponsored by, or have participated in advisory board meetings for Sanofi, Leo Pharma, Pfizer, Abbvie, Eli-Lilly


2 (EC)
















1. Consultation


Severity assessment

- QoL (dermatology life quality index (DLQI), based on questionnaire)
- HECSI (hand eczema severity score index), based on symptoms and area




10







2. Consultation



· Oral and written information

your time - determine relevance


· Durable small cards in plastic

(IEC) 13

2. Consultation (3 months later) • Subdiagnosis? What can patients do themselves to optimize the situation • Assessment of severity and QoL (improvement?) • Optimize topical treatment or start systemic treatment IEC

2. Consultation. Treatment • Topical treatment: Topical corticosteroids
 Calcineurin inhibitors • Physical treatment: • UV therapy • Systemic treatment*: • Alitretinoin (not in US) • Acitretin • Azathioprine Methotrexate
Cyclosporine
Dupilumab (IEC)

14



_

16

